Bristol Myers betaler $11 mia for halvpart i Biontech middel
-
"Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7.6 billion in milestones, gives BMS a 50% stake in one of the leading candidates in the hottest area of immuno-oncology."
Det er lige knap halvdelen af Biontechs marketcap, som i øvrigt stort set er dækket af kontanter.
-
Også den her nyhed fra i dag trods et temmelig dødt M&A-landskab:
Sanofi to snap up Blueprint Medicines and mastocytosis drug Ayvakit for $9.1B
https://endpoints.news/sanofi-to-snap-up-blueprint-medicines-and-mastocytosis-drug-ayvakit-for-9-1b/Relateret til BMS vedhæftet figur med kvartalsvise globale salgstal for PD-1-inhibitoren Opdivo.
-
Ivonescimab fra Summit Therapeutics er ogsaa en PD-1/VEGF-A inhibitor. Den er indtil videre kun godkendt i Kina.
2024-05-31
https://www.smmttx.com/pressrelease/ivonescimab-in-combination-with-chemotherapy-approved-in-china-by-nmpa-for-2l-egfrm-nsclc-based-on-harmoni-a-clinical-trial-positive-trend-observed-in-overall-survival-towards-ivonescimab-plus-chemo/
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind